SureTrader
Home > Boards > US OTC > Biotechs >

Nuo Therapeutics, Inc. (AURX)

AURX RSS Feed
Add AURX Price Alert      Hide Sticky   Hide Intro
Moderator: PyschoNoobStock
Search This Board: 
Last Post: 4/12/2018 4:18:14 PM - Followers: 3 - Board type: Free - Posts Today: 0

Nuo Therapeutics, Inc. (OTCQX: AURX)

Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1987 and is based in Gaithersburg, Maryland.
 
Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape.
 
http://www.nuot.com/
 

About Us

Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape.

Vision for Change

Through bold leadership, better clinical solutions, and products that add true value to a patient’s health, we aim to offer more effective and efficient therapies for healing.

Advancing Wound Care

Nuo Therapeutics’ flagship product, Aurix™, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. It is the only therapy of its kind that is FDA-cleared for use on ulcers and wounds of all types.

 

Management

Peter A. Clausen, Ph.D., Chief Science Officer
 

Peter A. Clausen, Ph.D., Chief Science Officer

Dr. Clausen joined Nuo Therapeutics in September 2008 and has more than 20 years of experience in the biotechnology industry. Prior to joining Nuo Therapeutics, Dr. Clausen was a founding member and Vice President of Research and Development at Marligen Bioscience, where he developed and commercialized innovative genomic and protein analysis products for the life sciences market. Dr. Clausen was the Manager of New Purification Technologies at Life Technologies and the Invitrogen Corporation. He also has significant experience within the commercial biotechnology industry developing peptide and small molecule therapeutics for application in the areas of inflammatory mediated disease and stem cell transplantation. He completed his post-doctoral training at the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy. Dr. Clausen earned his PhD in Biochemistry from Rush University in Chicago and a Bachelor of Science degree in Biochemistry from Beloit College.

 
David E. Jorden, CPA, Chief Executive Officer & Chief Financial Officer

David E. Jorden, CPA, Chief Executive Officer & Chief Financial Officer

David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.




Board of Directors
 

 

David E. Jorden, CPA, Chief Executive Officer & Chief Financial Officer

David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.

 

Paul D. Mintz, MD

Paul D. Mintz, MD was elected to the Nuo Therapeutics, Inc. Board of Directors, effective April 7, 2017. Dr. Mintz is currently the Senior Vice President and Chief Medical Officer of Verax Biomedical. Prior to joining Verax Biomedical in early 2016, Dr. Mintz served as Director, Division of Hematology Clinical Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration. Prior to that, for more than 30 years, Dr. Mintz was a member of the faculty of the University of Virginia School of Medicine, where he was a tenured Professor of Pathology and Internal Medicine. He also served as Vice-Chair of Pathology and Chief of the Division of Clinical Pathology, and as Medical Director of the Clinical Laboratories and Transfusion Medicine Services at the University of Virginia Health System. In addition, Dr. Mintz served as Co-Medical Director of Virginia Blood Services. Dr. Mintz is a former President of the American Association of Blood Banks (AABB), served on the AABB’s Board of Directors for nine years, and was a member of and chaired numerous AABB committees. Dr. Mintz is a recipient of the AABB’s John Elliott Memorial Award. He has also served as a member of the Board of Trustees of the National Blood Foundation. Dr. Mintz is the recipient of a Transfusion Medicine Academic Award from the National Heart, Lung and Blood Institute, and was an inaugural inductee into the National Blood Foundation Hall of Fame. He also served as a member of the Medicare Coverage Advisory Committee of the Centers for Medicare and Medicaid Services (CMS). Dr. Mintz is author or co-author of more than 100 articles and editorials spanning clinical practice, blood safety and the evaluation of new transfusion medicine technologies, and has designed and served as principal investigator for numerous clinical trials. He is the sole editor of all three editions of Transfusion Therapy: Clinical Principles and Practice (AABB Press) and has served on several journal editorial boards. Dr. Mintz earned his BA in Philosophy from the University of Rochester and received his MD with honors from the University of Rochester School of Medicine. Dr. Mintz brings considerable knowledge of platelet biology and transfusion medicine, along with senior regulatory and reimbursement experience to Nuo Therapeutics, and will be enormously valuable as the company strives to advance the Aurix System toward broader commercialization in the large and growing chronic wound care market.

C. Eric Winzer

C. Eric Winzer has served as Director since January 30, 2009. Mr. Winzer has over 30 years of experience in addressing diverse financial issues including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning and analysis, and accounting operations. Mr. Winzer has been the Chief Financial Officer at Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company, since May 2015. From June 2009 to April 2015 Mr. Winzer served as the Principal Accounting Officer, Senior Vice President of Finance, and Chief Financial Officer for OpGen Inc. (OPGN), a precision medicine company that went public in May 2015. Before his tenure with OpGen Inc., Mr. Winzer held multiple executive positions at Avalon Pharmaceuticals, Inc. (AVRX), a NASDAQ listed biotechnology company, including serving as its Chief Financial Officer and Executive Vice President, Principal Accounting Officer, and Secretary. Before joining Avalon Pharmaceuticals, Mr. Winzer held numerous senior financial positions over twenty years at Life Technologies Corporation (LIFE) (now part of Thermo Fisher Scientific (TMO)) and its predecessor companies, Invitrogen (IVGN) and Life Technologies, Inc. (LTEK). From 1980 to 1986, Mr. Winzer held various financial positions at Genex Corporation. Mr. Winzer has been an Independent Director at Nuo Therapeutics (f/k/a Cytomedix, Inc.) since January 30, 2009. Mr. Winzer holds a B.A. in Economics and Business Administration from Western Maryland College (now, McDaniel College) and an M.B.A. from Mount Saint Mary's University. Mr. Winzer was chosen to serve as a director of the Company in part because of his executive experience in the life sciences industry and his substantial financial knowledge and expertise.

Lawrence S. Atinsky

Lawrence S. Atinsky has served as a director since May 5, 2016. Mr. Atinsky is a Partner at Deerfield Management Company, LP (“Deerfield Management”), a healthcare investment firm focused on advancing healthcare through investment, information and philanthropy. He primarily focuses on the firm’s structured transactions and private equity investments. Prior to joining Deerfield Management, Mr. Atinsky was a partner of Ascent Biomedical Ventures, a healthcare focused private equity firm investing in early-stage biomedical and medical device companies. He has over 18 years of experience investing in healthcare companies and currently serves on the Board of FluoroPharma Medical, Inc. Mr. Atinsky earned a J.D. from New York University School of Law and B.A. degrees in Political Science and Philosophy from the University of Wisconsin-Madison, cum laude. Deerfield Management’s affiliates are currently the sole holders of our Series A Preferred Stock and Mr. Atinsky serves as their designee to our Board of Directors under the Certificate of Designations for our Series A Preferred Stock.

Scott M. Pittman

Scott M. Pittman has served as a director since May 5, 2016. Mr. Pittman has over 30 years in Hospital Executive management. He is a Chief Operating & Business Development Officer for Buchanan General Hospital, a Registered Representative with Calton & Associates, and a Principal of Hospital CEO Associates. He has served as CEO Florida Hospital Zephyrhills, FL, in senior executive positions with Adventist Health Systems, and in various hospital executive positions in southern West Virginia. Mr. Pittman has developed several multimillion dollar hospital and program service expansions, and healthcare entity acquisitions and mergers, and has served on numerous state and regional health planning organizations. He is a Magna cum Laude graduate of Southwestern Adventist University with B.S. & B.A. Degrees in Business and Religion, and a Masters of Hospital Administration from Medical College of Virginia. Mr. Pittman was chosen to serve as a director of the Company in part because of his extensive experience as a hospital executive.

 



The Aurix System™
 

About Aurix™

Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.

Broaden Your Reach

Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).

Aurix can be used successfully on patients with:

  • Tunneling
    Sinus tracts
    Bone and tendon exposure
    Hardware exposure

Flexibility for Patients and Providers

Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.

 

About Aurix™

Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.

Broaden Your Reach

Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).

Aurix can be used successfully on patients with:

  • Tunneling
    Sinus tracts
    Bone and tendon exposure
    Hardware exposure

Flexibility for Patients and Providers

Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.

Aurix

Harnessing the body’s natural healing power leads to fewer applications and less time-to-heal.

For more information visit www.AurixSystem.com

Video-Thumb

 

 

Nuo Therapeutics is committed to delivering the highest quality solutions in biodynamic tissue repair.

For more information about our company or our products, please contact or fill out the form on www.nuot.com/contact/

Corporate Offices
207A Perry Parkway, Suite 1
Gaithersburg, MD 20877

Nashville Office
618 Church St., Suite 305
Nashville, TN 37219

Phone
1.866.298.6633

Fax
1.240.499.2690

Email
info@nuot.com




 
SureTrader
AURX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
AURX News: Annual Report (10-k) 04/16/2018 04:38:15 PM
AURX News: Current Report Filing (8-k) 04/04/2018 05:16:55 PM
AURX News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 04/02/2018 10:18:50 AM
AURX News: Current Report Filing (8-k) 01/19/2018 04:36:43 PM
AURX News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 12/13/2017 11:54:22 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#84   Anybody here? TILIS 04/12/18 04:18:14 PM
#83   So a reverse split is coming here? Bankroll423 03/15/18 02:19:57 PM
#82   3 hour ride. All it ever was.. greaseball 03/07/18 02:10:17 PM
#81   It look like it will go back up.. PyschoNoobStock 02/26/18 01:50:46 PM
#80   Very risky stock with such low volume stocksplit123 02/22/18 02:47:00 PM
#79   Dollars coming taubytaub 02/22/18 02:14:36 PM
#78   This is not a good stock to enter stocksplit123 02/21/18 03:07:45 PM
#77   Timmmmmberrrrrr Penny Planet 02/21/18 02:27:29 PM
#76   Very triggered shareholders here Penny Planet 02/21/18 12:26:06 PM
#74   Whale bid was the clue to chuck taubytaub 02/21/18 12:13:34 PM
#72   Why so much dumping today? Dilution? Penny Planet 02/21/18 12:10:32 PM
#71   Agree.. Boom Time! PyschoNoobStock 02/21/18 11:47:52 AM
#70   WALL ON BID SIZE LARGEST SIZE SHES SEEN taubytaub 02/21/18 11:47:26 AM
#69   Will see break new high today? PyschoNoobStock 02/21/18 10:34:13 AM
#68   UP .54! PyschoNoobStock 02/21/18 10:25:57 AM
#67   Slap!!!! PyschoNoobStock 02/21/18 09:58:58 AM
#66   Strong bull stock. PyschoNoobStock 02/21/18 09:39:41 AM
#65   Unbelievable how well this performed yesterday, my 50K tdeck 02/21/18 06:44:18 AM
#64   Global Globoid Cell Leukodystrophy Treatment Market 2018: Novartis, PyschoNoobStock 02/21/18 01:19:38 AM
#63   Global Sandhoff Disease Therapeutics Sales Market Report 2018 PyschoNoobStock 02/21/18 01:16:49 AM
#62   wrong, their is more that's going on than stocksplit123 02/21/18 12:46:37 AM
#61   $AURX .. very strong day .. as expected farah2015 02/20/18 06:43:39 PM
#60   .575 hitting! PyschoNoobStock 02/20/18 03:19:43 PM
#59   So thin, explosive greaseball 02/20/18 03:13:32 PM
#58   UP .575! PyschoNoobStock 02/20/18 03:12:16 PM
#57   :) greaseball 02/20/18 03:11:34 PM
#56   Big buy coming! BOOM!! PyschoNoobStock 02/20/18 03:03:36 PM
#55   Breakout coming!! Hitting .555!!! PyschoNoobStock 02/20/18 03:02:29 PM
#54   UP .55 PyschoNoobStock 02/20/18 02:42:42 PM
#53   IF break .60 and .80.. Bluesky ahead. MACD PyschoNoobStock 02/20/18 01:03:29 PM
#52   If the volume hit 1 Million.. We would PyschoNoobStock 02/20/18 01:02:15 PM
#51   Stinky rich in my Vegas suite taubytaub 02/20/18 01:01:12 PM
#50   $.55 getting hits ... WarChest 02/20/18 01:00:47 PM
#49   THIN Levell 2 ASK!!! RUNNER IS HERE!!! PyschoNoobStock 02/20/18 12:58:57 PM
#48   $7.77 taubytaub 02/20/18 12:58:34 PM
#47   Up .56!! PyschoNoobStock 02/20/18 12:58:27 PM
#46   .55 hitting! PyschoNoobStock 02/20/18 12:58:05 PM
#45   WEEEEEEEE taubytaub 02/20/18 12:58:00 PM
#44   This could run to $10.00 EASY! PyschoNoobStock 02/20/18 12:57:30 PM
#43   UP .55!!! PyschoNoobStock 02/20/18 12:57:00 PM
#42   Breakout coming.. Levell 2 thin!! PyschoNoobStock 02/20/18 12:52:55 PM
#41   This is nuts. Wish I bought more taubytaub 02/20/18 12:52:52 PM
#40   UP .51!!! PyschoNoobStock 02/20/18 12:52:01 PM
#39   More volume coming.. Here we go!!!! Weeee!!!!!!!!! PyschoNoobStock 02/20/18 12:51:43 PM
#38   .44 hitting.. PyschoNoobStock 02/20/18 12:50:05 PM
#37   .44 up ~ WarChest 02/20/18 12:48:45 PM
#36   BOOOOM!!!!!!!!!!! PyschoNoobStock 02/20/18 12:48:44 PM
#35   UP .44 Broke new high PyschoNoobStock 02/20/18 12:45:54 PM
#34   Up .37 PyschoNoobStock 02/20/18 12:13:23 PM
#33   .34 up !!! WarChest 02/20/18 11:54:41 AM
PostSubject